BRIEF-Erytech Pharma reports full GRASPA Phase III results

<span id="midArticle_start"/> Erytech Pharma SA :

<span id="midArticle_0"/>* Reported on Monday complete Phase III results of itspivotal program with GRASPA in Acute Lymphoblastic Leukemia(ALL) and presented the design of the ongoing Phase IIb study inAcute Myeloid Leukemia (AML)

<span id="midArticle_1"/>* GRASPA in combination with chemotherapy demonstratedsustained asparaginase activity, which was superior compared toL-ASP, for the treatment of patients with ALL

<span id="midArticle_2"/> <span class="first-article-divide"/>* GRASPA demonstrated a significantly lower risk ofhypersensitivity reactions, compared to L-ASP

<span id="midArticle_3"/>* Treatment was generally well tolerated, with a lower riskof key events

<span id="midArticle_4"/> <span class="second-article-divide"/>Source text for Eikon:

<span id="midArticle_5"/> <span class="third-article-divide"/>Further company coverage:

<span id="midArticle_6"/>(Gdynia Newsroom)

<span id="midArticle_7"/>

via Smart Health Shop Forum http://ift.tt/1I7OAQa